leadf
logo-loader
viewBiocept Inc

Biocept proposed reverse stock split endorsed by corporate advisory firms

The reverse split would reduce Biocept's total number of shares at a ratio between 1:5 and 1:30 in order to meet the minimum price requirement of the Nasdaq

Nasdaq building
Biocept is developing Target Selector technology, which detects and isolates cancer biomarkers such as circulating tumor cells and cell-free circulating tumor DNA

Biocept Inc (NASDAQ:BIOC) told investors Thursday that corporate governance firms Institutional Shareholder Services (ISS) and Glass Lewis & Co have both recommended that stockholders vote in favor of the company’s proposed reverse stock split. 

The reverse split would reduce Biocept's total number of shares at a ratio between 1:5 and 1:30, propelling its share price above the $1 minimum closing price requirement for continued listing on the Nasdaq. 

Voting will be open through the conclusion of the company’s virtual annual meeting of stockholders, which will reconvene at 1:30 PT on July 31. Stockholders can register to attend here, and the deadline to do so is 5 pm Et on July 29.

READ: Biocept wins patent in Canada to further protect Target Selector liquid biopsy test technology

The company said it has until December 7 to satisfy the requirement or it will be subject to delisting. Biocept’s board of directors has also recommended stockholders vote to approve the proposal.

Shares of Biocept traded at $0.70 Thursday morning.

ISS and Glass Lewis are independent proxy advisory firms that offer voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.

Biocept is developing Target Selector technology, which detects and isolates cancer biomarkers such as circulating tumor cells and cell-free circulating tumor DNA. The San Diego company offers the tests commercially to doctors, hospitals, clinics and researchers, with a focus on lung, breast, gastric, colorectal and prostate cancers — which represent 45% of all metastatic cancers — as well as melanoma.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Biocept Inc

Price: 4.52 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $60.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 09/23/2020

2 min read